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INTRODUCTION
Rabies	is	a	fatal	disease	of	global	importance	
resulting	 in	 encephalitis	 affecting	 both	 humans	
and	 animals	 (Warrel,	 2004;	 Rupprecht	 et al.,	
2008;	Tordo	et	al	2005)	produced	by	a	lyssavirus	





benefits	 of	 biotechnology	 development	 (Rosset,	
1985).	 For	 rabies	 immunization	 of	 domestic	
animals	 inactivated	 vaccines	 are	 used.	 These	
vaccines	have	different	degrees	of	purity	and	after	
vaccination	 may	 occur	 neurological	 accidents	
which	are	 caused	by	 the	presence	of	whole	viral	
particle,	 or	 incomplete	 inactivation	 or	 adjuvants	
used.	 To	 overcome	 these	 drawbacks	 subunit	
vaccines	 (Yang	 et al.,	 2008;Yuan	 et al.,	 2008;	
Yusibov	 et al.,	 1997,	 Zhou	 et al.,	 2010)	 why	 not	
use	whole	 viral	 particles,	 vaccines	 that	 use	 only	
the	viral	genome	and	recombinant	vaccines		have	
been	 researched	 and	 tested	 (Szelechowski	et al.,	
2012).	All	these	new	types	of	vaccines	have	been	
shown	to	represent	an	alternative	to	conventional	
vaccines.	 In	 addition,	 because	 of	 the	 current	
economic	 crisis	 that	 shows	 no	 sign	 they	 would	
end	 soon,	 vaccine	manufacturers	 are	 looking	 for	
solutions	on	the	production	process,	and	to	solve	
old	problems	that	can	occur	after	vaccination.	To	
eliminate	 these	 drawbacks	 a	 promising	 solution	
is	the	use	of	vaccinal	vectors	obtained	using	DNA	
recombinant	technology.		
In	 this	 paper	 we	 developed	 a	 new	 vector	
derived	 from	 CAV-2	 expressing	 the	 G	 protein	 of	
rabies	 virus	which	 could	 bring	 improvements	 in	
animal	rabies	vaccination	strategy.
MATERIALS AND METHODS
Dog	 kidney	 cells	 (DK-cre),	 were	 grown	
as	 monolayers	 in	 Dulbecco’s	 modiﬁed	 Eagle’s	
medium	 (DMEM)	 supplemented	 with	 10%	 fetal	
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Rabies	 is	a	 fatal	disease	known	since	ancient	 times,	and	 the	only	weapon	against	 them	 is	 the	vaccination.	
Starting	with	the	19th	century	has	developed	rabies	vaccines	which	registered	a	real	success,	but	the	current	trend	
is	 to	 search	 for	 safer	and	more	economical	 formulas.	 In	 this	paper	we	designed	a	 structural	model	of	a	 rabies	
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2	 program.	 For	 titration	 we	 used	 real	 time	 PCR	
(Roche-Applied),	 PCR	 (Eppendorf)	 and	 the	
biophotometer	Eppendorf.
RESULTS AND DISCUSSIONS
Rabies	 virus	 glycoprotein	 which	 represent	




CMV	 was	 digested	 and	 separated	 using	 SwaI	
and	Mbo	 I	 restriction	 enzyme.	 The	 plasmid	 thus	
obtained	was	designated	 as	 pNavette	 311-319	G	
CMV	and	it	has	a	length	of	6111	bp.
The	next	level	of	this	research	was	homologous	
recombination	 using	DHC	 cloning	 subpopulation	
(Invitrogen)	 of	 pNavette	 311-319	 G/GFP	 CMV	
which	 was	 digested	 by	 AscI	 and	 SwaI	 thus	
obtaining	pCAV311-319nuII	(33473pb)	plasmid.	
That	 plasmid	 was	 digested	 by	 NotI	 and	
result	pCAV311-319G/GFP	CMV	(33473bp).	This	
one	 was	 digested	 by	 AscI	 and	 result	 the	 vector	
pRecCAV2	CMV	G/GFP	(35531bp)	who	was	after	
that	transfected,	multiplied	and	purified.	





a	 concentration	 of	 1010,4	 infectious	 particles	 in	
2	 μl	 of	 vaccine	 solution.	 The	 biophotometer	
measurement	 at	 DO
260






of	 current	 preparations.	 Since	 the	 pioneering	
activity	 of	 the	 early	 1990s,	 immunisation	 with	
plasmid	DNA	has	proven	to	be	a	valid	alternative	
to	 conventional	 vaccines,	 both	 for	 human	 and	
veterinarian	 use.	 In	 this	 study,	 our	 team	 has	
developed	a	new	rabies	vaccine	candidate	derived	






manufacturing	 process,	 rather	 than	 more,	 and	
possibly	even	one	vaccination	process.	The	vector	
only	 expresses	 the	 antigens	 of	 the	 pathogen	 that	
are	required	to	elicit	a	protective	immune	response	
and,	 therefore,	 reduces	 or	 eliminates	 chance	 of	
being	 exposed	 to	 all	 pathogenic	 disease	 as	 a	 live	
vaccine	 killed	 or	 modified	 (Schultz,	 1999).	 At	
the	 level	 of	 research	 for	 the	 development	 of	 new	
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vaccines	have	been	used	as	vectors	many	types	of	




providing	 a	 multivalent	 vaccine	 approach	
(Perkus	 et al.,	 1985,	 Boyle	 et al.,	 2004),	 	 and	 the	
recombinant	vaccinia	virus	to	be	used	 in	the	ﬁeld	
was	 the	 Copenhagen	 strain	 expressing	 the	 rabies	
virus	surface	glycoprotein	(Blancou	et al.,	1986)	in	
1982.	From	then	until	now	many	strains	have	been	
engineered	 to	 express	 a	 variety	 of	 antigens	 from	
a	number	of	 pathogens	 in	 various	 animal	 species	
(Brun	 et al.,	 2008).	 Several	 baculoviruses	 (Abe	 et 
al.,	2003)	and	herpesviruses			have	been	engineered	
to	serve	as	vaccine	vectors	(Xuan	et al.,	1998).	RNA	
viruses	 classiﬁed	 in	 the	 family	 Paramyxoviridae,	
Bunyaviridae,	 Rhabdoviridae,	 Coronaviridae,	
Retroviridae,	 Alphaviridae	 or	 Flaviviridae	 have	
served	as	vaccine	vector	for	some	pathogens.	
Adenoviruses	 (Ad)	 have	 been	 isolated	 from	
humans	 and	 many	 animals,	 including	 bovine,	
ovine,	 porcine,	 canine	 and	 avian	 species.	Human	
Ad	are	by	far	the	best	characterised,	and	the	most	
tested	 was	 the	 vectors	 derived	 from	 serotype	 5	
of	Ad	(Ad5).	Vectors	derived	from	several	animal	
adenoviruses	 have	 been	 evaluated	 as	 vaccines	
delivered	 by	 parenteral	 routes	 with	 promising	
results.	In	this	experiment	was	developed	a	vector	











Rabies	 virus	 glycoprotein	 were	 used	 in	
different	 vaccine	 construction	 regardless	 of	 type	
of	 vector	 used,	 mainly	 because	 has	 increased	
immunogenic	 potential,	 but	 were	 also	 used	
formulations	 with	 rabies	 virus	 nucleoprotein	 as	
insert	(Prehaud	et	al	1999).
Fig.2.	Separation	of	pNavette	311-319	G/GFP	CMV	using	AscI	and	SwaI	restriction	enzyme












glycoprotein	which	may	 represent	 an	 alternative	
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